Covaxin well tolerated in those not yet vaccinated in US: Study

"Phase II/III observer-blind, immuno-bridging and broadening study was done to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein," it said, adding that currently approved vaccines in the US target only S-protein antigen.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v65OB1z
via IFTTT